Phase 1 Dose-Escalation Study of 90yttrium-Labeled Anti-CD22 Epratuzumab Tetraxetan in Adults with Refractory/Relapsed CD22+B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Authors :: Chevallier, Patrice
Eugene, Thomas
Robillard, Nelly
Isnard, Françoise
Nicolini, Franck E
Escoffre-Barbe, Martine
Huguet, Françoise
Hunault, Mathilde
Marcais, Antoine
Guillaume, Thierry
Delaunay, Jacques
Peterlin, Pierre
Thomas, Xavier
Ifrah, Norbert
Lapusan, Simona
bodet-Milin, Caroline
faivre Chauvet, Alain
Le Houerou, Claire
Goldenberg, David M
Wegener, William A
Kraeber-Bodere, Françoise
Source :: Blood; November 2014, Vol. 124 Issue: 21 p3708-3708, 1p
Publication Year :: 2014
Abstract: Background: Prognosis of relapsed/refractory acute lymphoblastic leukemia (ALL) in adults is dismal. CD22 is highly expressed in patients with B-ALL. Epratuzumab (hLL2) is a humanized monoclonal antibody targeting CD22 surface antigen. We performed a standard 3+3 phase 1 study to assess the feasibility, tolerability, and efficacy of a 90yttrium-labeled anti-CD22 epratuzumab tetraxetan (90Y-DOTA-hLL2) radioimmunotherapy (RIT) in adults with refractory/relapsed CD22+B-ALL.

Full Text Access

Tools